MyMD Pharmaceuticals Enrolls First Patient in Stage 2 Medical Trial of MYMD-1 as a Therapy for Delaying Aging and also Expanding Healthy Life Expectancy

MyMD Pharmaceuticals, Inc. MYMD Stock (” MyMD” or “the Business”), a medical phase pharmaceutical firm dedicated to extending healthy and balanced life-span, today revealed that the initial patient has been registered in the Business’s Stage 2 scientific trial of lead candidate MYMD-1, a dental immune regulatory authority medicine, as a treatment for delaying aging as well as broadening healthy and balanced life expectancy.

The key endpoint for the Stage 2 double-blind, placebo-controlled professional test is to accomplish a decrease in the flowing degrees of (TNF-α), tumor death variable receptor I (TNFRI) as well as IL-6. TNF-α and also IL-6 are the healthy proteins in the body that cause swelling and assist trigger the process of aging. The secondary measures of the test will certainly be the safety, tolerability, and pharmacokinetics in this populace of people.

” In a Phase 1 clinical test of MYMD-1, we showed the medicine’s statistically considerable effectiveness in decreasing levels of TNF-α, a key player in creating pathological aging, in the blood. The FDA has accepted TNF-α decrease as the key endpoint for our Phase 2 research, which our company believe settings us well for a successful Phase 2 result,” claimed Chris Chapman, M.D., President, Director as well as Chief Medical Policeman of MyMD. “The initiation of patient registration in this research developments our mission to slow the aging procedure, avoid loss of muscle cells in aging, limitation frailty, as well as prolong healthy life expectancy.”

MyMD has stated that there are no FDA-approved medications for treating aging disorders as well as prolonging healthy and balanced lifespan people, a market expected to be a minimum of $600 billion by 20251 according to a significant financial investment financial institution. TNF-α blockers are one of the most proposed drugs by earnings, a worldwide market of roughly $40 billion each year,2 and also, according to Nature Aging journal,3 a stagnation in maturing that would boost life expectancy by one year deserves $38 trillion and by one decade is worth $367 trillion.

In addition to aging, MYMD-1’s distinctive action in managing the immune system and treating persistent swelling is being established for the therapy of autoimmune disease, including rheumatoid arthritis (RA), numerous sclerosis (MS), diabetes mellitus, as well as inflammatory bowel disease.

” We plan to begin writing protocols for a Phase 2 pilot research study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman kept in mind. “The rising occurrence of rheumatoid joint inflammation and other autoimmune and also inflammatory diseases are driving demand for TNF inhibitors like MYMD-1, and we believe our by mouth administered drug with really low toxicity would certainly be disruptive to the $60 billion market for RA if authorized by the FDA for this indication.”

Rheumatoid joint inflammation influences roughly 40 million individuals around the world.4.

Concerning MYMD-1.

Initially developed for autoimmune conditions, MYMD-1’s main purpose is to slow the aging procedure, protect against sarcopenia as well as frailty, and also expand healthy lifespan. Since it can go across the blood-brain barrier and get to the central nervous system (CNS), MYMD-1 is likewise placed to be a possible treatment for brain-related conditions. Its mechanism of activity as well as efficiency in conditions consisting of several sclerosis (MS) as well as thyroiditis have actually been examined with cooperations with a number of scholastic establishments. MYMD-1 is also showing guarantee in pre-clinical studies as a potential treatment for article- COVID-19 problems and also as an anti-fibrotic and also anti-proliferation restorative.

MYMD-1 has revealed effectiveness in pre-clinical research studies in controling the immune system by executing as a selective prevention of lump necrosis factor-alpha (TNF-α), a motorist of chronic swelling. Unlike various other treatments, MYMD-1 has actually been shown in these pre-clinical research studies to selectively obstruct TNF-α when it becomes overactivated in autoimmune conditions as well as cytokine tornados, but not obstruct it from doing its typical task of being a first responder to any regular type of modest infection. MYMD-1’s simplicity of dental dosing is one more differentiator compared to currently readily available TNF-α blockers, all of which need distribution by shot or mixture. No authorized TNF inhibitor has ever before been dosed orally. Additionally, the medication is not immunosuppressive as well as has actually not been revealed to create the serious negative effects common with typical therapies that treat swelling.

Concerning MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a scientific phase pharmaceutical business dedicated to prolonging healthy life-span, is focused on developing two unique healing systems that treat the root causes of condition rather than just attending to the symptoms. MYMD-1 is a drug platform based on a medical stage small molecule that manages the immune system to control TNF-α, which drives persistent swelling, as well as various other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to postpone aging, increase long life, and also deal with autoimmune conditions and also COVID-19- connected anxiety. The Company’s second drug system, Supera-CBD, is being established to treat chronic pain, addiction as well as epilepsy. Supera-CBD is an unique artificial by-product of cannabidiol (CBD) as well as is being developed to attend to as well as improve upon the swiftly expanding CBD market, which includes both FDA approved medications as well as CBD items not currently managed as medications. For more details, see www.mymd.com.